TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06048016

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planning
Description: Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
Study: NCT04103372

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
Study: NCT04103372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiologist training
Description: Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
Study: NCT06513429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Description: IM19 CAR-T cells by intravenous infusion.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
Study: NCT05043610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)
Description: cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
Study: NCT06027086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRP-104
Description: Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T9
Description: Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
Study: NCT04652258

Intervention type: DRUG
Group type: OTHER
Intervention: Actemra
Description: Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
Study: NCT05321953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy Care
Description: Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy Care
Description: Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Inspiratory Muscle Training
Description: The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
Study: NCT06396481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vγ9Vδ2 T cell
Description: The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vγ9Vδ2 T cell
Description: The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vγ9Vδ2 T cell
Description: The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
Study: NCT05444504

Intervention type: DEVICE
Group type: OTHER
Intervention: Cup
Description: an insertable vaginal cup ('cup')

Intervention type: DEVICE
Group type: OTHER
Intervention: Cup
Description: an insertable vaginal cup ('cup')

Intervention type: DEVICE
Group type: OTHER
Intervention: Cup+
Description: the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
Study: NCT05932810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study: NCT05444504

Intervention type: DEVICE
Group type: OTHER
Intervention: Cup+
Description: the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
Study: NCT04974879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Oral Tablet
Description: Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.
Study: NCT05932810

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
Study: NCT06351410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Wearing Contact Lens
Description: Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
Study: NCT06394999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Description: Once-weekly oral mifepristone 50 mg
Study: NCT06302634

Intervention type: OTHER
Intervention: Exercise-based cardio-oncology rehabilitation
Description: Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.

Intervention type: OTHER
Intervention: Exercise-based cardio-oncology rehabilitation
Description: Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
Study: NCT06510465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
Study: NCT05696366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
Study: NCT05459714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCE for obese patients
Description: Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
Study: NCT04873661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis group intervention
Description: See arm description
Study: NCT05696366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Volagidemab
Description: Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volagidemab
Description: Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
Study: NCT04873661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive trance group intervention
Description: See arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation group intervention
Description: See arm description
Study: NCT05115201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with antibiotics
Description: Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing only
Description: Patients will be treated with scaling and root planing
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T10
Description: Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
Study: NCT05144061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2398 Tablets
Description: Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
Study: NCT06483633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT + CPT, HIIT + CPT, SIT + CPT
Description: Single acute intervention, each exercise mode had a washout period of at least 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT + CPT, HIIT + CPT, SIT + CPT
Description: Single acute intervention, each exercise mode had a washout period of at least 7 days.
Study: NCT06330753

Intervention type: OTHER
Group type: OTHER
Intervention: Trauma-informed Care Plan-
Description: Per our IRB protocol patient participates will be consented for this study. A member of the healthcare team ( licensed nurse, social worker or doctor) will conduct the TICP with the patient. The TICP will be placed in the electronic medical record right below the patients name. The workflow is such is that if any plan of care placed on the Storyboard (under the patient's name) should be read first before engaging with a patient.
Study: NCT04325815

Intervention type: DEVICE
Intervention: CADDIE- Computer Aided (AI) Device used in Endoscopy
Description: 1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation
Study: NCT06513767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia Dental Ceramics
Description: This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
Study: NCT05153486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ablation
Description: Patients receive surgical ablation.
Study: NCT05734872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Technology
Description: Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
Study: NCT04729049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae plane Block
Description: Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
Study: NCT05734872

Intervention type: OTHER
Group type: OTHER
Intervention: Routine mental health course training
Description: Conduct mental health education for patients by making a speech.
Study: NCT06296810

Intervention type: DEVICE
Intervention: aDBS
Description: adaptive deep brain stimulation
Study: NCT06499948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Spironolactone followed by Dapagliflozin followed by their combination
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
Study: NCT04729049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia with intravenous morphine
Description: Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia with intravenous morphine
Description: Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
Study: NCT06062576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
Study: NCT06499948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Dapagliflozin followed by Spironolactone followed by their combination
Description: After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.